标题：Tonghua Dongbao Pharmaceutical Clinical trials for a major oral diabetes drug approved
发布日期：2016-02-18 11:20:57
内容： Event: The Company announced that on Feb 15 2016 it received approvingdocument from SFDA for clinical trial of a major oral diabetes drug,Rpaglinide and Metformin Hydrochloride Tablet (RMH tablets). Comments: To conduct EB test ASAP as it has obtained the approval forclinical trials. Fierce competition in the future as several peers are on the samestage. Well positioned in low-tier markets, the Company will likelyfacilitate sales of this drug through its close ties with doctors,huge user base and other marketing resources Risks: slower than expected R&D and cut in prices for insulin in medicine procurement tenders. Reiterate BUY. As a leading maker of insulin and first-mover in the field of diabetes management, wereiterate the Companyˇs 2015-17E EPS of Rmb0.42/0.55/0.72, apply 58x 2016E PE based oncomparablesˇ valuation, arrive at the TP of Rmb31.90 and reiterate BUY.
发布日期：2016-02-18 11:20:57
内容： Event: The Company announced that on Feb 15 2016 it received approvingdocument from SFDA for clinical trial of a major oral diabetes drug,Rpaglinide and Metformin Hydrochloride Tablet (RMH tablets). Comments: To conduct EB test ASAP as it has obtained the approval forclinical trials. Fierce competition in the future as several peers are on the samestage. Well positioned in low-tier markets, the Company will likelyfacilitate sales of this drug through its close ties with doctors,huge user base and other marketing resources Risks: slower than expected R&D and cut in prices for insulin in medicine procurement tenders. Reiterate BUY. As a leading maker of insulin and first-mover in the field of diabetes management, wereiterate the Companyˇs 2015-17E EPS of Rmb0.42/0.55/0.72, apply 58x 2016E PE based oncomparablesˇ valuation, arrive at the TP of Rmb31.90 and reiterate BUY.
